194 related articles for article (PubMed ID: 24975891)
21. Clinical effects of long-term (36-month) lanthanum carbonate administration in hemodialysis patients in Japan.
Kishi Y; Obara Y; Hara K; Yamashiro H; Kurosawa N; Takada D
Ther Apher Dial; 2014 Jun; 18 Suppl 1():9-13. PubMed ID: 24953760
[TBL] [Abstract][Full Text] [Related]
22. [The influence of short-term magnesium carbonate treatment on calcium-phosphorus balance in dialysis patients].
Zwiech R; Dryja P; Łacina D; Króliczak V; Chrul S; Kacprzyk F
Wiad Lek; 2011; 64(1):9-14. PubMed ID: 21812357
[TBL] [Abstract][Full Text] [Related]
23. Sevelamer hydrochloride in peritoneal dialysis patients: results of a multicenter cross-sectional study.
Ramos R; Moreso F; Borras M; Ponz E; Buades JM; Teixidó J; Morey A; Garcia C; Vera M; Doñate MT; de Arellano MR; Barbosa F; González MT
Perit Dial Int; 2007; 27(6):697-701. PubMed ID: 17984434
[TBL] [Abstract][Full Text] [Related]
24. Does concomitant administration of sevelamer hydrochloride and lanthanum carbonate modify the control of phosphatemia?
Senatore M; Coppolino G; Papalia T; Greco R; Lofaro D; Bonofiglio R
Eur Rev Med Pharmacol Sci; 2011 Nov; 15(11):1352-4. PubMed ID: 22195373
[No Abstract] [Full Text] [Related]
25. One year efficacy and safety of lanthanum carbonate for hyperphosphatemia in Japanese chronic kidney disease patients undergoing hemodialysis.
Shigematsu T;
Ther Apher Dial; 2010 Feb; 14(1):12-9. PubMed ID: 20438515
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of sucroferric oxyhydroxide treatment in Japanese hemodialysis patients and its effect on gastrointestinal symptoms.
Suzuki D; Ichie T; Hayashi H; Sugiura Y; Sugiyama T
Pharmazie; 2017 Feb; 72(2):118-122. PubMed ID: 29441865
[TBL] [Abstract][Full Text] [Related]
27. Effect of sevelamer on mineral and lipid abnormalities in hemodialysis patients.
Hamida FB; Fatma LB; Barbouch S; Kaaroud H; Helal I; Hedri H; Abdallah TB; Maiz HB; Kheder A
Saudi J Kidney Dis Transpl; 2008 Mar; 19(2):183-8. PubMed ID: 18310864
[TBL] [Abstract][Full Text] [Related]
28. Lanthanum carbonate: a postmarketing observational study of efficacy and safety.
Rombolà G; Londrino F; Corbani V; Falqui V; Ardini M; Zattera T;
J Nephrol; 2012; 25(4):490-6. PubMed ID: 22476966
[TBL] [Abstract][Full Text] [Related]
29. Bixalomer in Hyperphosphatemic Patients With Chronic Kidney Disease Not on Dialysis: Phase 3 Randomized Trial.
Akizawa T; Origasa H; Kameoka C; Tsukada J; Kuroishi K; Yamaguchi Y
Ther Apher Dial; 2016 Dec; 20(6):588-597. PubMed ID: 27896908
[TBL] [Abstract][Full Text] [Related]
30. A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients.
Floege J; Covic AC; Ketteler M; Rastogi A; Chong EM; Gaillard S; Lisk LJ; Sprague SM;
Kidney Int; 2014 Sep; 86(3):638-47. PubMed ID: 24646861
[TBL] [Abstract][Full Text] [Related]
31. Comparison of sevelamer hydrochloride and sevelamer carbonate: risk of metabolic acidosis and clinical implications.
Pai AB; Shepler BM
Pharmacotherapy; 2009 May; 29(5):554-61. PubMed ID: 19397463
[TBL] [Abstract][Full Text] [Related]
32. Intensified treatment of hyperphosphatemia associated with reduction in parathyroid hormone in patients on maintenance hemodialysis.
Chen L; He JX; Chen YY; Ling YS; Lin CH; Guan TJ
Ren Fail; 2018 Nov; 40(1):15-21. PubMed ID: 29295646
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of SBR759, a novel calcium-free, iron(III)-based phosphate binder, in Asian patients undergoing hemodialysis: A 12-week, randomized, open-label, dose-titration study versus sevelamer hydrochloride.
Chen JB; Chiang SS; Chen HC; Obayashi S; Nagasawa M; Hexham JM; Balfour A; Junge G; Akiba T; Fukagawa M
Nephrology (Carlton); 2011 Nov; 16(8):743-50. PubMed ID: 21854503
[TBL] [Abstract][Full Text] [Related]
34. Influence of sevelamer on mineral metabolism and hyperparathyroidism in Japanese hemodialysis patients.
Inoue T; Nagatoya K; Kagitani M; Shibahara N; Ueda H; Katsuoka Y; Ohashi S; Kitagawa Y; Nishimoto K; Yasuda H;
Ther Apher Dial; 2007 Jun; 11(3):210-4. PubMed ID: 17498003
[TBL] [Abstract][Full Text] [Related]
35. Effect of gastric acid suppression with pantoprazole on the efficacy of sevelamer hydrochloride as a phosphate binder in haemodialysis patients: a pilot study.
Lai B; Cervelli MJ
Nephrology (Carlton); 2012 May; 17(4):402-6. PubMed ID: 22329674
[TBL] [Abstract][Full Text] [Related]
36. Three-year follow-up of lanthanum carbonate therapy in hemodialysis patients.
Takeuchi K; Matsuda E; Sekino M; Hasegawa Y; Kamo Y; Kikuchi N; Sekino H
Ther Apher Dial; 2013 Apr; 17 Suppl 1():15-21. PubMed ID: 23586508
[TBL] [Abstract][Full Text] [Related]
37. Dose-response efficacy and safety of PA21 in Japanese hemodialysis patients with hyperphosphatemia: a randomized, placebo-controlled, double-blind, Phase II study.
Koiwa F; Terao A
Clin Exp Nephrol; 2017 Jun; 21(3):513-522. PubMed ID: 27389681
[TBL] [Abstract][Full Text] [Related]
38. Effectiveness and safety of extended-release nicotinic acid for reducing serum phosphorus in hemodialysis patients.
Aramwit P; Srisawadwong R; Supasyndh O
J Nephrol; 2012; 25(3):354-62. PubMed ID: 21748722
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of nicotinamide in the management of hyperphosphatemia in pediatric patients on regular hemodialysis.
El Borolossy R; El Wakeel LM; El Hakim I; Sabri N
Pediatr Nephrol; 2016 Feb; 31(2):289-96. PubMed ID: 26420678
[TBL] [Abstract][Full Text] [Related]
40. A randomized, double-blind, crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis.
Delmez J; Block G; Robertson J; Chasan-Taber S; Blair A; Dillon M; Bleyer AJ
Clin Nephrol; 2007 Dec; 68(6):386-91. PubMed ID: 18184521
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]